Chat with Paul Stoffels
Vice Chairman of Johnson & Johnson
About Paul Stoffels
In the early 2000s, while leading J&J’s global R&D, he championed a high-risk bet on long-acting antiretroviral formulations, years before the field accepted slow-release delivery as viable for HIV. His team’s work on cabotegravir, co-developed with ViiV Healthcare, redefined adherence paradigms and laid groundwork for the first injectable PrEP regimen approved by the FDA in 2021. Unlike peers who prioritized oral monotherapies, Stoffels insisted on combinatorial pharmacokinetics, matching half-lives of paired agents to avoid resistance spikes, a principle now embedded in WHO treatment guidelines. Trained in clinical virology at KU Leuven and shaped by Belgium’s multilingual, consensus-driven scientific culture, he consistently bridges translational gaps: from bench assays in Leiden labs to real-world rollout in sub-Saharan clinics. His leadership during the 2009 H1N1 pandemic wasn’t about speed alone, it was about embedding ethics into trial design, halting enrollment when early data showed disproportionate pediatric mortality. That tension, between urgency and rigor, is his signature.
Why Chat with Paul Stoffels?
Paul Stoffels is one of the most influential figures in Science & Technology. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on vice chairman of johnson & johnson topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.
Start Your Conversation with Paul Stoffels
Ask questions, explore ideas, and learn something new. Free with an account, and no card.
Chat with Paul Stoffels NowCall Paul Stoffels and talk out loud
You do not have to type. Call Paul Stoffels and hear the answer in their own voice, in this browser, with nothing to install. Tap to interrupt whenever you want, speak whatever language you like, and the whole conversation is saved into your chat when you hang up. 20 minutes of calls free every 30 days when you sign in, no card.
Call Paul Stoffels How calling worksConversation Starters
Not sure where to begin? Try asking Paul Stoffels:
- “How did your team solve the crystallization instability that nearly derailed cabotegravir’s Phase II?”
- “What ethical guardrails did you implement for the HVTN 705/HPX2008 HIV vaccine trial in South Africa?”
- “Why did J&J pivot from protease inhibitors to integrase strand transfer inhibitors in the mid-2000s?”
- “How does Belgium’s regulatory tradition influence your approach to EU-first clinical development?”
